immunosuppression

(redirected from Immunosuppressive therapy)
Also found in: Thesaurus, Medical, Legal, Encyclopedia.
Related to Immunosuppressive therapy: Immunosuppressive medications

im·mu·no·sup·pres·sion

 (ĭm′yə-nō-sə-prĕsh′ən, ĭ-myo͞o′-)
n.
Suppression of the immune response, as by drugs or radiation, in order to prevent the rejection of grafts or transplants or to control autoimmune diseases. Also called immunodepression.

im′mu·no·sup·pres′sant (-prĕs′ənt) n.
im′mu·no·sup·pressed′ (-prĕst′) adj.
im′mu·no·sup·pres′sive adj.

immunosuppression

(ˌɪmjʊnəʊsəˈprɛʃən)
n
(Medicine) medical suppression of the body's immune system, esp in order to reduce the likelihood of rejection of a transplanted organ

im•mu•no•sup•pres•sion

(ˌɪm yə noʊ səˈprɛʃ ən, ɪˌmyu-)

n.
the inhibition of the normal immune response because of disease, the administration of drugs, or surgery.
[1960–65]
im`mu•no•sup•press′, v.t. -pressed, -press•ing.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.immunosuppression - lowering the body's normal immune response to invasion by foreign substances; can be deliberate (as in lowering the immune response to prevent rejection of a transplanted organ) or incidental (as a side effect of radiotherapy or chemotherapy for cancer)
immunological disorder - a disorder of the immune system
Translations

immunosuppression

[ɪˈmjʊːnəʊsəˈpreʃən] Ninmunosupresión f

immunosuppression

n inmunosupresión f
References in periodicals archive ?
However, immunosuppressive therapy also opens the doors to more harmful conditions like infections.
Of these patients, the proportions of receiving immunosuppressive therapy or supportive therapy were compared between PLA2R-associated and non-PLA2R-associated iMN patients whose clinical data were available after 1 year since the biopsy.
Adults with IBD should be assessed for prior exposure to varicella and vaccinated if naive prior to initiation of immunosuppressive therapy when possible.
Cytomegalovirus (CMV) is a well-known cause of life-threatening opportunistic infection in immunocompromised patients, such as those with acquired immunodeficiency syndrome (AIDS), receiving immunosuppressive therapy and those having undergone organ transplantation.
Regarding the risk of hepatosplenic T-cell lymphoma in patients exposed to immunosuppressive therapy, Dr.
Europe, and Australia identified no unknown safety concerns and confirmed that the risk for PML increases with longer use of natalizumab and with any prior use of immunosuppressive therapy.
The aims of this study were to determine the clinical success rates, effect of neutropenia on treatment success rates, risk factors related to mortality, and survival in patients who developed HAP while receiving immunosuppressive therapy.
Some areas examined include costimulation blockade as a regulatory t- cell inducing therapy, strategies for T cell depletion to prevent graft versus host disease, leukocyte intracellular cytokines in lung transplant patients, indications and management of m-TOR inhibitors after liver transplantation, and the role of pharmacogenomics in tailoring immunosuppressive therapy for liver transplant recipients.
Thus, the researchers are now turning their attention to possible benefits of immunosuppressive therapy on other health risks associated with inflammatory diseases.
Since the late 1980s, several reports have described a prolongation of time to transplantation through the administration of immunosuppressive therapy for patients diagnosed by endomyocardial biopsy.
The fibrocalcific nodules found on the chest radiograph imply that either 1) the patient might have had histoplasmosis for years and it became disseminated because of immunosuppressive therapy for rheumatoid arthritis or 2) the patient was reinfected with the calcified lesions that resulted from prior histoplasmosis.
Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should use CellCept.